Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of March 2021. The report details the results of an Extraordinary General Meeting held on March 31, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial statements.
Material Changes
There are no financial material changes reported in this document. The primary corporate action was the withdrawal of Agenda Item 2 regarding "Amendments of the Articles of Association" prior to the meeting.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of shareholder voting results. No guidance, outlook, risks, or contingencies are discussed in this specific filing.
- Agenda Item 1: Shareholders approved the election of Alan Colowick as a member of the Board of Directors until the end of the next Annual General Meeting.
- Agenda Item 2: Withdrawn by the Board before the vote.
Key Facts for Investor Verification
- Alan Colowick has been elected to the Board of Directors.
- Proposed amendments to the Articles of Association were withdrawn and not voted upon.
- Refer to Exhibit 99.1 (Press Release dated March 31, 2021) for additional details on the meeting results.